S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

Notice: Trading of Xilio Therapeutics halted at 06:55 AM EST due to "News pending".
$1.08
+0.44 (+68.75%)
(As of 03/28/2024 ET)
Today's Range
$1.06
$1.93
50-Day Range
$0.55
$0.83
52-Week Range
$0.49
$3.67
Volume
34.38 million shs
Average Volume
786,220 shs
Market Capitalization
$29.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Xilio Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Xilio Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1,832 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.76) to ($1.89) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.94 out of 5 stars

Medical Sector

893rd out of 938 stocks

Pharmaceutical Preparations Industry

402nd out of 425 stocks

XLO stock logo

About Xilio Therapeutics Stock (NASDAQ:XLO)

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

XLO Stock Price History

XLO Stock News Headlines

Why Is Xilio Therapeutics (XLO) Stock up 168% Today?
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Xilio Therapeutics Inc XLO
Xilio Therapeutics GAAP EPS of -$0.61
Xilio Therapeutics Appoints Katarina Luptakova As CMO
Q2 2023 Xilio Therapeutics Inc Earnings Call
XLO - Xilio Therapeutics, Inc.
See More Headlines
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/01/2021
Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XLO
Fax
N/A
Employees
81
Year Founded
N/A

Profitability

Net Income
$-88,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.85 per share

Miscellaneous

Free Float
26,275,000
Market Cap
$44.06 million
Optionable
Not Optionable
Beta
-0.32
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Rene Russo BCPS (Age 49)
    Pharm.D., President, CEO & Director
    Comp: $888.49k
  • Mr. Kevin M. Brennan (Age 54)
    Senior VP of Finance & Accounting
  • Mr. Christopher Frankenfield
    Chief Operating Officer
  • Dr. Uli Bialucha Ph.D.
    Chief Scientific Officer
  • Julissa Viana
    Vice President of Corporate Communications
  • Ms. Stacey J. Davis
    Chief Business Officer
  • Dr. Katarina Luptakova M.D.
    Chief Medical Officer
  • Dr. Scott Coleman Ph.D.
    Chief Development Officer

XLO Stock Analysis - Frequently Asked Questions

Should I buy or sell Xilio Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares.
View XLO analyst ratings
or view top-rated stocks.

How have XLO shares performed in 2024?

Xilio Therapeutics' stock was trading at $0.55 at the beginning of the year. Since then, XLO shares have increased by 96.4% and is now trading at $1.08.
View the best growth stocks for 2024 here
.

Are investors shorting Xilio Therapeutics?

Xilio Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 57,600 shares, an increase of 171.7% from the February 29th total of 21,200 shares. Based on an average daily trading volume, of 222,200 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.4% of the company's stock are sold short.
View Xilio Therapeutics' Short Interest
.

When is Xilio Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our XLO earnings forecast
.

How were Xilio Therapeutics' earnings last quarter?

Xilio Therapeutics, Inc. (NASDAQ:XLO) released its quarterly earnings results on Wednesday, December, 1st. The company reported ($21.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by $19.67.

When did Xilio Therapeutics IPO?

Xilio Therapeutics (XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share.

Who are Xilio Therapeutics' major shareholders?

Xilio Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Octagon Capital Advisors LP (6.48%), Bridgeway Capital Management LLC (0.56%) and Citadel Advisors LLC (0.19%). Insiders that own company stock include Bain Capital Life Sciences Inv, Rock Springs Capital Managemen and Venture Fund Xi LP Atlas.
View institutional ownership trends
.

How do I buy shares of Xilio Therapeutics?

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XLO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners